Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees. The inducement stock options have a grant date of February 28, 2023 and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--( BUSINESS WIRE )--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process.

Biocept to Explore Strategic Alternatives and Implement Restructuring Plan

Biocept, Inc. (NASDAQ:BIOC ) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain - LHA Investor Relations Sam Riccitelli - Chairman and Interim President and Chief Executive Officer Antonino Morales - Interim Chief Financial Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Operator Good day, and welcome to the Biocept Third Quarter Financial Results Conference Call. All participants are in a listen-only mode.

Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript

Biocept Inc (NASDAQ:BIOC) has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metastasis.   Commenting on its third-quarter results, Biocept CEO Samuel Riccitelli said the company was executing well on its strategy to generate further evidence to secure higher reimbursement for CNSide and support its adoption into clinical care guidelines.

Biocept reports 176% year-over-year jump in orders for CNSide assay

SAN DIEGO--( BUSINESS WIRE )--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a business update.

Biocept Reports Third Quarter 2022 Financial Results

Biocept Inc (NASDAQ:BIOC) said it has appointed certified public accountant Quyen Dao-Haddock to its board of directors, bringing her more than 20 years of financial and accounting experience to the audit committee.  This increases board membership to eight for the San Diego-based provider of molecular diagnostic assays, products and services.

Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee

SAN DIEGO--( BUSINESS WIRE )--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept's Audit Committee.

Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

Biocept Inc (NASDAQ:BIOC) said it is participating in a study evaluating biomarkers associated with central nervous system (CNS) metastasis in patients with metastatic breast cancer and brain metastases and/or leptomeningeal disease.  The study will look at cerebrospinal fluid tumor and the immune cell microenvironment to better understand treatment response, prognosis, and treatment resistance that may improve the management of CNS disease in patients with metastatic breast cancer, the company said.

Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer

SAN DIEGO--( BUSINESS WIRE )--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic pilot study to evaluate the cerebrospinal fluid tumor and immune cell microenvironment in patients with metastatic breast cancer and brain metastases and/or leptomeningeal disease. The study is designed to identify biomarkers associated with central nervous system (CNS) metastasis, enabling a better understanding of treatment response, prognosis, and treatment resistance that may improve the management of CNS disease in patients with metastatic breast cancer.

Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System

Biocept Inc (NASDAQ:BIOC) told investors it was continuing to position itself as a "leader in neurological tumor diagnostics" as the company released second-quarter results, which included the first revenue from a biopharma firm using its CNSide in a clinical trial. Biocept's CNSide cerebrospinal fluid assay can detect cancer cells that have metastasized to the central nervous system.

Biocept continuing to position itself as 'leader in neurological tumor diagnostics' as it posts second quarter results

SAN DIEGO--( BUSINESS WIRE )--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business update.

Biocept Reports Second Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m.

Biocept to Present at the LD Micro Main Event XV

Biocept Inc (NASDAQ:BIOC) revealed that it has expanded the commercial availability of CNSide, which is based on its proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets, to patients with metastatic melanoma. Previously validated for lung, breast, and all other carcinomas, the San Diego, California-based company's CNSide is a proprietary cerebrospinal fluid (CSF) assay designed to better detect metastatic cancers involving the central nervous system (CNS).

Biocept expands availability of its CNSide assay for most cancers that metastasize to the central nervous system

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patients with metastatic melanoma.

Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held today, October 14 at 1 p.m.

Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held October 14 at 1 p.m. Eastern time featuring case studies presented by leading neuro-oncologists who have used the company's CNSide assay in the management of patients with confirmed or suspected central nervous system metastasis. The webinar will feature key opinion leaders Priya U. Kumthekar, MD of Northwestern University

Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising Biocept that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. The delay is related to the ongoing accounting review of Biocept's financial statements as of and for the three months ended June 30, 2022, which ongoing review includes the analysis of previously reported material weaknesses and matters related to the U.S. He

Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th straight year by Accounting Today. RSM replaces Mayer Hoffman McCann P.C. (“MHM”), which notified the company on April 7, 2022 of

Biocept Appoints RSM as Independent Auditor

Plus Therapeutics Inc

Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord.  Under the multi-year agreement, Biocept's cerebrospinal fluid (CSF) assay CNSide1 will be employed in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM).

Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up t

Biocept to Hold Business Strategy Conference Call Today

Biocept Inc (NASDAQ:BIOC) posted first-quarter results that saw its revenue jump 12% year-over-year on the back of its RT-PCR coronavirus (COVID-19) testing services. For the period ended March 31, 2022, the San Diego, California-based provider of molecular diagnostic assays, products, and services, reported revenue of $19.9 million, compared to $17.8 million in 1Q 2021.

Biocept sees 1Q net revenue rise 12% driven by its coronavirus testing services

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update. “Net revenues for the first quarter increased 12% to $19.9 million, driven by RT-PCR COVID-19 testing services,” said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. “We continued to generate strong growth with our proprietary neuro-oncology

Biocept Reports First Quarter 2022 Financial Results

Biocept, Inc. has reported a strong rise in full-year 2021 revenue due to growth in volumes for reverse transcription (RT) PCR coronavirus (COVID-19) testing.  The company, a leading provider of molecular diagnostic assays, products and services, said net revenues for the year to December 31, 2021, reached $61.2 million, a 123% increase from $27.5 million in 2020.

Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business update. “During the fourth quarter we expanded our CNSide customer base to include several additional prestigious academic institutions while generating sequential-quarter volume growth,” said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO.

News for Biocept Stock (BIOC)